136 related articles for article (PubMed ID: 1830225)
1. The effect of recombinant alpha-interferon on natural killer cell activity and clinical course in patients with myelodysplastic syndrome.
Yataganas X; Eliopoulos G; Koulocheri S; Viniou N; Plata E; Panagiotidis P; Vayopoulos G; Meletis J; Fessas P
Ann Hematol; 1991 Jun; 62(6):225-9. PubMed ID: 1830225
[TBL] [Abstract][Full Text] [Related]
2. Effect of recombinant alpha-interferon administration on peripheral blood lymphocyte subpopulations and natural killer cell activity in patients with refractory anemia with excess of blasts.
Eliopoulos G; Coulocheri S; Vaiopoulos G; Alexandrakis M; Ganotakis E; Eliopoulos A; Yataganas X
Nouv Rev Fr Hematol (1978); 1991; 33(1):21-4. PubMed ID: 1945821
[TBL] [Abstract][Full Text] [Related]
3. Alpha-interferon in myelodysplasia; clinical observations and effects on NK cells.
Galvani DW; Nethersell AB; Cawley JC
Leuk Res; 1988; 12(3):257-62. PubMed ID: 3163399
[TBL] [Abstract][Full Text] [Related]
4. Defective mitogen-induced cellular cytotoxicity in myelodysplastic syndromes. Recovery after alpha-interferon administration.
Eliopoulos G; Constantopoulou M; Coulocheri S; Vaiopoulos G; Eliopoulos A; Yataganas X
Anticancer Res; 1991; 11(2):685-9. PubMed ID: 2064322
[TBL] [Abstract][Full Text] [Related]
5. A trial of recombinant alpha 2 interferon in the myelodysplastic syndromes: I. Clinical results.
Elias L; Hoffman R; Boswell S; Tensen L; Bonnem EM
Leukemia; 1987 Feb; 1(2):105-10. PubMed ID: 3478534
[TBL] [Abstract][Full Text] [Related]
6. Different sensitivity to interleukin 4 of interleukin 2- and interferon alpha-induced CD69 antigen expression in human resting NK cells and CD3+, CD4-, CD8- lymphocytes.
Gerosa F; Tommasi M; Carra G; Gandini G; Tridente G; Benati C
Cell Immunol; 1992 May; 141(2):342-51. PubMed ID: 1533569
[TBL] [Abstract][Full Text] [Related]
7. Immune defects in families and patients with xeroderma pigmentosum and trichothiodystrophy.
Mariani E; Facchini A; Honorati MC; Lalli E; Berardesca E; Ghetti P; Marinoni S; Nuzzo F; Astaldi Ricotti GC; Stefanini M
Clin Exp Immunol; 1992 Jun; 88(3):376-82. PubMed ID: 1535035
[TBL] [Abstract][Full Text] [Related]
8. Clonally expanded CD3+, CD4-, CD8- cells bearing the alpha/beta or the gamma/delta T-cell receptor in patients with the lymphoproliferative disease of granular lymphocytes.
Pandolfi F; Foa R; De Rossi G; Zambello R; Chisesi T; di Celle PF; Migone N; Casorati G; Scarselli E; Ensoli F
Clin Immunol Immunopathol; 1991 Sep; 60(3):371-83. PubMed ID: 1830831
[TBL] [Abstract][Full Text] [Related]
9. CD3+, CD4-, CD8- large granular T-cell lymphoproliferative disorder.
Sun T; Cohen NS; Marino J; Koduru P; Cuomo J; Henshall J
Am J Hematol; 1991 Jul; 37(3):173-8. PubMed ID: 1650132
[TBL] [Abstract][Full Text] [Related]
10. Impaired alpha-interferon production and natural killer activity in blood mononuclear cells in myelodysplastic syndromes.
Okabe M; Minagawa T; Nakane A; Sakurada K; Miyazaki T
Scand J Haematol; 1986 Aug; 37(2):111-7. PubMed ID: 3489981
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms accounting for the impaired natural-killer cell activity in refractory anaemia with excess of blasts.
Eliopoulos GD; Coulocheri SA; Eliopoulos AG; Katrinakis G; Karkavitsas N; Kyriakou D; Vaiopoulos G; Foudoulakis A
Eur J Haematol; 1992 May; 48(5):237-43. PubMed ID: 1379537
[TBL] [Abstract][Full Text] [Related]
12. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
[TBL] [Abstract][Full Text] [Related]
13. Decreased lymphocyte subsets and K-cell activity in iron deficiency anemia.
Santos PC; Falcão RP
Acta Haematol; 1990; 84(3):118-21. PubMed ID: 2147088
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of the subsets of lymphocytes and their activated status in patients with myelodysplastic syndrome].
Yang J; Wang C; Xie KC; Yan SK; Gao YR; Cai Q; Qin YW; Wan LP; Cai Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):708-13. PubMed ID: 16928305
[TBL] [Abstract][Full Text] [Related]
15. Effect of alpha-interferon on the immune system of patients with hairy cell leukemia.
Foa R; Fierro MT; Lusso P; Bonferroni M; Raspadori D; Buzzi M; Zinzani PL; Resegotti L; Lauria F
Leukemia; 1987 Apr; 1(4):377-9. PubMed ID: 3499543
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced myelodysplastic syndromes with recombinant interferon-alpha 2b.
Aul C; Gattermann N; Schneider W
Eur J Haematol; 1991 Jan; 46(1):11-6. PubMed ID: 1988303
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell function and number of peripheral blood are not altered in recurrent aphthous ulceration.
Pedersen A; Pedersen BK
Oral Surg Oral Med Oral Pathol; 1993 Nov; 76(5):616-9. PubMed ID: 7504229
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes.
Nand S; Ellis T; Messmore H; Fisher SG; Gaynor E; Fisher RI
Leukemia; 1992 Mar; 6(3):220-3. PubMed ID: 1564960
[TBL] [Abstract][Full Text] [Related]
19. Dichotomy of two CD8+ lymphocyte subsets in HIV infection. Depletion of CD8+ CD3- and expansion of CD8+ CD3+ subsets: consequence on the CD4/CD8 ratio.
Mansour I; Doinel C; Rouger P
Clin Exp Immunol; 1991 Sep; 85(3):481-4. PubMed ID: 1832598
[TBL] [Abstract][Full Text] [Related]
20. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
